ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

NCR3LG1

natural killer cell cytotoxicity receptor 3 ligand 1 · also DKFZp686O24166, B7-H6 · Receptor ligands

1 program in company-led studies act on NCR3LG1, from 1 company: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049ruleBoehringer Ingelheim–phase 130 runningCD3ENCIt

Also acted on by the same programs

Conditions their studies are in

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.